Castle Biosciences Inc. (CSTL)
Castle Biosciences Statistics
Share Statistics
Castle Biosciences has 28.01M shares outstanding. The number of shares has increased by 2.03% in one year.
| Shares Outstanding | 28.01M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.98% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 27.14M |
| Failed to Deliver (FTD) Shares | 40 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 1.68M, so 6% of the outstanding shares have been sold short.
| Short Interest | 1.68M |
| Short % of Shares Out | 6% |
| Short % of Float | 6.2% |
| Short Ratio (days to cover) | 4.81 |
Valuation Ratios
The PE ratio is -10.06 and the forward PE ratio is -16.15.
| PE Ratio | -10.06 |
| Forward PE | -16.15 |
| PS Ratio | 2.63 |
| Forward PS | 2.5 |
| PB Ratio | 1.48 |
| P/FCF Ratio | -30.05 |
| PEG Ratio | n/a |
Enterprise Valuation
Castle Biosciences Inc. has an Enterprise Value (EV) of 494.86M.
| EV / Earnings | -8.61 |
| EV / Sales | 2.25 |
| EV / EBITDA | -10.99 |
| EV / EBIT | -7.28 |
| EV / FCF | -25.71 |
Financial Position
The company has a current ratio of 6.2, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.2 |
| Quick Ratio | 6.04 |
| Debt / Equity | 0.04 |
| Total Debt / Capitalization | 3.77 |
| Cash Flow / Debt | -0.37 |
| Interest Coverage | -6179.73 |
Financial Efficiency
Return on equity (ROE) is -0.15% and return on capital (ROIC) is -16.75%.
| Return on Equity (ROE) | -0.15% |
| Return on Assets (ROA) | -0.13% |
| Return on Capital (ROIC) | -16.75% |
| Revenue Per Employee | 309.56K |
| Profits Per Employee | -80.94K |
| Employee Count | 710 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 5.66 |
Taxes
| Income Tax | 101.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 7.98% in the last 52 weeks. The beta is 0.98, so Castle Biosciences 's price volatility has been higher than the market average.
| Beta | 0.98 |
| 52-Week Price Change | 7.98% |
| 50-Day Moving Average | 28.7 |
| 200-Day Moving Average | 26.36 |
| Relative Strength Index (RSI) | 45.27 |
| Average Volume (20 Days) | 409.71K |
Income Statement
In the last 12 months, Castle Biosciences had revenue of 219.79M and earned -57.47M in profits. Earnings per share was -2.14.
| Revenue | 219.79M |
| Gross Profit | 174.81M |
| Operating Income | -67.98M |
| Net Income | -57.47M |
| EBITDA | -45.02M |
| EBIT | -67.98M |
| Earnings Per Share (EPS) | -2.14 |
Balance Sheet
The company has 98.84M in cash and 15.34M in debt, giving a net cash position of 83.51M.
| Cash & Cash Equivalents | 98.84M |
| Total Debt | 15.34M |
| Net Cash | 83.51M |
| Retained Earnings | -218.37M |
| Total Assets | 514.57M |
| Working Capital | 300.48M |
Cash Flow
In the last 12 months, operating cash flow was -5.63M and capital expenditures -13.62M, giving a free cash flow of -19.25M.
| Operating Cash Flow | -5.63M |
| Capital Expenditures | -13.62M |
| Free Cash Flow | -19.25M |
| FCF Per Share | -0.72 |
Margins
Gross margin is 79.53%, with operating and profit margins of -30.93% and -26.15%.
| Gross Margin | 79.53% |
| Operating Margin | -30.93% |
| Pretax Margin | -26.1% |
| Profit Margin | -26.15% |
| EBITDA Margin | -20.49% |
| EBIT Margin | -30.93% |
| FCF Margin | -8.76% |
Dividends & Yields
CSTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -8.02% |
| FCF Yield | -2.58% |
Analyst Forecast
The average price target for CSTL is $40.5, which is 51.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $40.5 |
| Price Target Difference | 51.9% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 6.85 |
| Piotroski F-Score | 7 |